个人情况介绍、概览

丁怀伟，男，博士，特聘教授。2006年毕业于沈阳药科大学，获中药学学士学位，2009年于同校获天然药物化学硕士学位，2012年于同校获药物化学博士学位，博士论文于清华大学深圳研究生院联合培养完成，2019年评为沈阳药科大学副教授，2020年评为沈阳药科大学特聘教授。参与国家自然科学基金面上项目2项；主持辽宁省科技厅项目1项，教育厅项目1项，沈阳药科大学科研基金项目2项，完成横向课题17项。目前在 Clinical and Translational Medicine，Cell Death and Disease，Cancers，European Journal of Medicinal Chemistry，Bioorganic Chemistry，European Journal of Organic Chemistry等杂志发表SCI文章20余篇。申请中国专利15项，现已授权9项。

人才称号、社会兼职等

Acta Pharmaceutica Sinica B青年编委。

主要研究方向

研究方向一：基于靶点的抗肿瘤化合物的设计、合成与生物活性研究
研究方向二：基于活性天然产物的结构优化

纵向项目

1.PI3K/c-Met双靶点抑制剂的设计合成与抗肿瘤作用机制研究，2019-ZD-0446，辽宁省科学技术厅。

横向项目

无

论文

1.A comprehensive description of GluN2B-selective N-methyl-D-aspartate (NMDA) receptor antagonists.European Journal of Medicinal Chemistry .2020.(IF=5.572)
2.A novel 4-aminoquinazoline derivative, DHW-208, suppresses the growth of human breast cancer cells by targeting the PI3K/AKT/mTOR pathway.Cell Death and Disease.2020.(IF=6.304)
3.Design, synthesis and evaluation of some 1,6-disubstituted-1H-benzo[d]imidazoles derivatives targeted PI3K as anticancer agents.Bioorganic Chemistry.2019.(IF=4.831)
4.Design, synthesis, and biological evaluation of some novel 4-aminoquinazolines as Pan-PI3K inhibitors.Bioorganic & Medicinal Chemistry.2019.(IF=3.073)
5.Design, synthesis and biological evaluation of harmine derivatives as potent GSK-3β/DYRK1A dual inhibitors for the treatment of Alzheimer's disease.European Journal of Medicinal Chemistry.2021.(IF=6.514)
6.DZW-310, a novel phosphoinositide 3-kinase inhibitor, attenuates the angiogenesis and growth of hepatocellular carcinoma cells via PI3K/AKT/mTOR axis.Biochemical Pharmacology.2022.
7.DHW-221, a Dual PI3K/mTOR Inhibitor, Overcomes Multidrug Resistance by Targeting P-Glycoprotein (P-gp/ABCB1) and Akt-Mediated FOXO3a Nuclear Translocation in Non-small Cell Lung.Frontiers in Oncology.2022.
8.Facile synthesis of C1-substituted β-carbolines as CDK4 inhibitors for the treatment of cancer..Bioorganic Chemistry.2022.
9.Design, synthesis, and biological evaluation of β-carboline 1,3,4-oxadiazole based hybrids as HDAC inhibitors with potential antitumor effects..Bioorganic & Medicinal Chemistry Letters.2022.
10.Exploration of 4-(1H-indol-3-yl)cyclohex-3-en-1-amine analogues as HDAC inhibitors: Design, synthesis, biological evaluation and modelling studies..Bioorganic & Medicinal Chemistry Letters.2022.

学术成果

无